METABOLIC & WEIGHT RESEARCH / FAQ
Questions the Data Can Answer
Direct, citation-anchored responses to the questions most commonly asked about tesamorelin and retatrutide — drawn from the peer-reviewed literature and regulatory record.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified at the N-terminus to resist enzymatic cleavage by DPP-IV and extend plasma stability. It binds the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile release of the body's own growth hormone. The resulting GH drives hepatic IGF-1 production, and together GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue. It is FDA-approved as a prescription drug for a specific indication: reducing excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [2]. All use outside that indication is off-label.
What does tesamorelin do in the body?
Within its studied population (HIV adults with lipodystrophy), tesamorelin reduces visceral adipose tissue, trunk fat, and hepatic fat while increasing lean body mass. A 2026 meta-analysis of five RCTs quantified the mean VAT reduction at 27.71 cm2 (P<0.001), trunk fat at -1.18 kg, hepatic fat fraction at -4.28%, and lean mass gain at +1.42 kg [1]. In a separate 2014 JAMA trial it produced a VAT treatment effect of -42 cm2 and hepatic fat reduction of -2.9% at six months [3]. These effects are conditional on continuous dosing — visceral fat reaccumulates within weeks of stopping [5].
How does tesamorelin work?
Tesamorelin activates the GHRH receptor on the anterior pituitary, triggering the Gs/cAMP/PKA signaling cascade and stimulating GH secretion in the body's natural pulsatile pattern. That GH pulse drives hepatic IGF-1 production, and the GH/IGF-1 axis promotes lipolysis — fat mobilization — with preferential activity in visceral (abdominal) depots rather than subcutaneous fat. In healthy men, two weeks of tesamorelin increased mean overnight GH by 0.5 µg/L (P=0.004) and IGF-1 by 181 µg/L (P<0.0001) without affecting fasting glucose or insulin sensitivity [4]. By amplifying the body's own GH rhythm rather than supplying exogenous GH, the mechanism differs importantly from recombinant GH therapy.
Will tesamorelin help me lose belly fat?
The published trials that measured belly fat reduction were conducted exclusively in HIV-positive adults on antiretroviral therapy experiencing lipodystrophy — a specific, drug-induced redistribution of fat. That is the only population where tesamorelin has demonstrated this effect in controlled trials, and the only population for which it carries FDA approval [2]. Whether equivalent visceral-fat reductions occur in non-HIV adults is mechanistically plausible (the GHRH receptor exists in non-HIV people too) but has not been validated in large RCTs. This site does not recommend any use and lists no dose. Anyone considering this for any purpose should consult a licensed clinician.
What does retatrutide do?
Retatrutide activates three metabolic receptors simultaneously: the GLP-1 receptor (appetite suppression, insulin secretion), the GIP receptor (further insulin augmentation, adipose lipolysis), and the glucagon receptor (energy expenditure, thermogenesis). In a 48-week Phase 2 obesity trial, once-weekly retatrutide at 12 mg produced a mean -24.2% body-weight change versus -2.1% with placebo [11]. In a separate 36-week Phase 2 type 2 diabetes trial, retatrutide 12 mg reduced HbA1c by 2.02 percentage points and body weight by 16.94% [12]. It is investigational — not approved by any regulatory agency as of mid-2026.
How does retatrutide work?
Retatrutide is a triple incretin receptor agonist: one molecule engaging GLP-1R, GIPR, and GCGR simultaneously. Cryo-EM structures confirm this triple binding at atomic resolution [9]. The GLP-1 arm drives the dominant appetite suppression through GLP-1R activation and delayed gastric emptying. The GIP arm augments glucose-dependent insulin secretion and modulates fat-cell lipolysis. The glucagon arm, operating at a controlled agonist level, increases energy expenditure by activating thermogenic programs via cAMP/PKA signaling — the mechanism proposed to explain why retatrutide's weight-loss signal exceeds dual GLP-1/GIP agonists. Relative potency: approximately 8.9-fold versus native GIP at GIPR, 0.3-fold versus native glucagon at GCGR, 0.4-fold versus native GLP-1 at GLP-1R [9].
How to reconstitute retatrutide?
This desk does not provide reconstitution or preparation instructions for any peptide. Retatrutide is an investigational compound with no approved formulation or dispensing pathway outside clinical trials. In those trials it was supplied as a pre-formulated subcutaneous injection by the trial sponsor under controlled conditions. Any reconstitution of research-grade peptide material — which lacks verified identity, purity, and sterility — outside a clinical trial and without qualified laboratory oversight introduces serious safety risks. This site is a literature digest; it describes study designs and outcomes, not preparation or administration procedures.
Is retatrutide FDA approved?
No. Retatrutide (LY3437943) is not approved by the FDA or any other regulatory agency as of mid-2026. It is in the TRIUMPH Phase 3 clinical program under Eli Lilly. All published efficacy and safety data come from Phase 1 and Phase 2 clinical trials. It is not available as a prescription drug and has no approved indication [8][11]. Research-grade material sold outside clinical trials is unregulated, of unverified composition, and outside any clinical oversight. The FDA issued over 50 warning letters to retatrutide vendors in 2025.
How do tesamorelin and retatrutide compare for visceral fat?
They approach visceral fat from different angles and have been studied in different populations. Tesamorelin has precise, RCT-derived visceral-fat measurements: a 2026 meta-analysis found a mean VAT reduction of 27.71 cm2 (P<0.001) across five HIV-lipodystrophy trials [1], and the 2014 JAMA trial measured -42 cm2 at six months [3]. Retatrutide has not published dedicated visceral-fat CT or MRI data from its obesity trials; the liver-fat MASLD substudy showed -82.4% relative liver fat reduction at 24 weeks at 12 mg [10], and bodyweight data imply significant fat loss (-24.2% total weight [11]) but without the compartment-level precision of tesamorelin's imaging endpoints. The two are not directly comparable on the VAT dimension — different populations, different measurement approaches, different mechanisms.
What are the main side effects reported for retatrutide in trials?
In Phase 2 clinical trials, the most common adverse events were gastrointestinal: nausea (up to 45% at the highest dose), vomiting, diarrhea, constipation, and decreased appetite. These were dose-related, predominantly mild to moderate, and the principal driver of the 18% discontinuation rate at the highest dose in the obesity trial [11]. A dose-dependent increase in resting heart rate — approximately 5-7 bpm at high doses, peaking around 24 weeks — was consistently observed across trials, attributed to the glucagon receptor's cardiac chronotropy. Injection-site reactions occurred in approximately 8% of participants. No severe hypoglycemia was reported in non-diabetic subjects; participants on background insulin required dose adjustments [12].
Is tesamorelin banned in sport?
Yes. Tesamorelin is prohibited in sport by the World Anti-Doping Agency under Prohibited List category S2 — peptide hormones, growth factors, related substances and mimetics — as a GHRH analogue. This prohibition applies both in-competition and out-of-competition [7]. The classification follows directly from its mechanism: tesamorelin elevates endogenous GH and IGF-1, which are themselves prohibited. Athletes subject to anti-doping rules should treat tesamorelin as prohibited regardless of the medical indication or prescribing status in their jurisdiction.